BASKING RIDGE, NJ, May 13, 2009-
i3 announced today that its Spanish entity was named one of the top 10 places to work in Spain among companies of 100 to 250 employees. The Best Workplaces 2009 award from Great Place to Work® Institute Spain was awarded during a ceremony in Madrid Monday.
Companies are selected for the Best Companies lists primarily on the basis of their employees' responses to the
Great Place to Work Trust Index
, a proprietary employee survey developed by the Great Place to Work Institute. Employees evaluated the working atmosphere on: credibility, respect, fairness, pride and camaraderie.
“To be counted among the short list of companies known to be regarded by their employees as excellent worksites is a true honor and a goal which we consciously pursue every day here at i3,” said Anna Gibernau, Managing Director for i3 in Spain. “As a pharmaceutical services company, we strive for the highest level of quality in all we do, beginning with the environment we provide for our employees.”
Since 2003 an annual list of 100 Best Workplaces in 15 European countries has been identified and published in leading national European magazines and newspapers. Each year, the Great Place to Work® Institute produces various
Best Companies to Work For
lists in the U.S., including Fortune's 100
Best Companies to Work For®
in America
. The Institute uses the same selection methodology for the 30 international lists. Its approach is based on the major findings of 20 years of research - that trust between managers and employees is the primary defining characteristic of the very best workplaces. At the heart of the Institute’s definition of a great place to work—a place where employees "trust the people they work for, have pride in what they do, and enjoy the people they work with"—is the idea that a great workplace is measured by the quality of the three, interconnected relationships that exist there:
· The relationship between employees and management.
· The relationship between employees and their jobs/company.
· The relationship between employees and other employees.
About i3
i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit
www.i3global.com
.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.